Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00290069|
Recruitment Status : Unknown
Verified February 2006 by Sociedad Andaluza de Trasplantes de Organos y Tejidos.
Recruitment status was: Not yet recruiting
First Posted : February 10, 2006
Last Update Posted : May 15, 2007
|Condition or disease||Intervention/treatment||Phase|
|Kidney Diseases Graft Rejection||Drug: Tacrolimus Drug: Rapamycin||Phase 4|
The study population characteristics raise the need to establish a treatment regime that assures suitable intensity immunosuppression to avoid the appearance of rejection episodes, but minimizes the doses to prevent over-immunosuppression in a population with a theoretic minor immune response.
On the other hand, the delay in the introduction of calcineurin inhibitors will prevent increasing the risk of early graft dysfunction allowing the highest post-transplant renal recovery in organs with less operative mass and greater sensibility to the nephrotoxic effect of these drugs.
The results of several studies confirm the goodness of regimes that include low doses of calcineurin inhibitors, delay their introduction or avoid them.
Nevertheless, although it is standard practice to evaluate the effectiveness of the regimes for a time to assure, with certainty, the response to the treatments, these follow-ups are still relatively short to assure the efficacy for a long-term study and to detect the problems. The studies with a high number of patients and long follow-up periods are difficult, so several authors have proposed different alternatives of control in a short-term study that could be useful as surrogate markers or predictive efficacy variables for the long term.
If the drug or study regime is efficient, the observed change after the transplantation surgery will have to be fast and objective. The increase of serum creatinine between 6 and 12 months post-transplant is a reliable marker of graft failure risk, and the magnitude of the serum creatinine change in these months is a marker of the relationship with long-term survival. For that reason, renal function (serum creatinine) is included as a main efficacy variable.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||94 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparative Study of Tacrolimus and Rapamycin to Evaluate the Renal Function in Patients Older Than 50 Years, Receptors of a Kidney From a Donor Older Than 55 Years in a Mycophenolate Mofetil and Daclizumab Immunosuppressor Regime|
- Serum creatinine at 6 months
- Calculated creatinine clearance (Cockroft Gault)
- Acute rejection rate at 6 months and time until first rejection
- Patient and graft survival at 6 months
- Rate and length of the delay in the graft function defined as dialysis in the first week post-transplant
- Treatment failure at 6 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00290069
|Complejo Hospitalario Universitario de Santiago||Not yet recruiting|
|Santiago de Compostela, La Coruña, Spain, 15706|
|Contact: Rafael Romero, MD|
|Principal Investigator: Rafael Romero, MD|
|Hospital General Universitario Gregorio Marañón||Not yet recruiting|
|Madrid, Spain, 28007|
|Contact: Fernando Anaya, MD|
|Principal Investigator: Fernando Anaya, MD|
|Hospital Universitario Ramón y Cajal||Not yet recruiting|
|Madrid, Spain, 28034|
|Contact: Roberto Marcén, MD|
|Principal Investigator: Roberto Marcén, MD|
|Hospital Universitario 12 de Octubre||Not yet recruiting|
|Madrid, Spain, 28041|
|Contact: José L Morales, MD|
|Principal Investigator: José L Morales, MD|
|Hospital Universitario de Canarias||Not yet recruiting|
|Santa Cruz de Tenerife, Spain, 38320|
|Contact: Domingo Hernández, MD|
|Principal Investigator: Domingo Hernández, MD|
|Hospital Universitario Marqués de Valdecilla||Not yet recruiting|
|Santander, Spain, 39008|
|Contact: Juan C Ruiz San Millán, MD|
|Principal Investigator: Juan C Ruiz San Millán, MD|
|Hospital Universitario La Fe||Not yet recruiting|
|Valencia, Spain, 46009|
|Contact: Jaime Sánchez Plumed, MD|
|Principal Investigator: Jaime Sánchez Plumed, MD|
|Principal Investigator:||Miguel A Gonzalez Molina, MD||Sociedad Andaluza de Trasplantes de Organos y Tejidos|